Affymax (AFFY +3.1%) catches a bid after stating it will receive a $5M milestone payment from...

|By:, SA News Editor

Affymax (AFFY +3.1%) catches a bid after stating it will receive a $5M milestone payment from Takeda Pharmaceutical related to the development of its Peginesatide drug for treating anemia in dialysis patients, following the acceptance of a marketing application by Euro regulators. Affymax shot higher in December after an FDA advisory panel recommended Peginesatide be approved.